Fig. 4: PD-L1 antibody conjugated NP for delivering PLK1 inhibitor volasertib (p-iPLK1-NP; ARAC).
From: Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
a Synthesis scheme. Nanoparticle images are re-printed with permission from Wiley18; © 2022 Wiley-VCH GmbH. b Hydrodynamic size by dynamic light scattering (DLS). c Cell viability by CTG assay of LLC-JSP cells treated with volasertib (iPLK1) or iPLK1-NP; all having equivalent volasertib dose as specified. Data presented as mean ± SD from 4 independent samples; ****P < 0.0001 (Unpaired t-test; two-tailed). d Cell viability by CTG assay of LLC-JSP cells treated with iPLK1-NP or ARAC (p-iPLK1-NP) at equivalent NP and volasertib dose. Data presented as mean ± SD from 5 independent samples; ns – not significant (Unpaired t-test; two-tailed). (e, f) PD-L1 surface expression of the cells treated with PBS, PD-L1 antibody (50 µg/ml), iPLK1-NP (with 210 ng/ml volasertib), or ARAC (with 210 ng/ml volasertib and 1.68 µg/ml antibody) for 2 h and 2 days. Data presented as mean MFI from biological duplicates, 10,000 events collected per sample. Source data are provided as a Source Data file.
